Sponsors › Innovent Biologics
Innovent Biologics
Every GLP‑1 and incretin trial, approval and scheduled result we hold for Innovent Biologics, drawn from ClinicalTrials.gov and Drugs@FDA.
Innovent Biologics is a commercial sponsor with 13 trials in the incretin class on file here, across 3 molecules. The programme is split between 4 early-stage trials and 9 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2026-09-24.
- Molecules
- dulaglutide · mazdutide · semaglutide
- Trials on file
- 13
- Active trials
- 6
- Results scheduled
- 4
- Approved FDA submissions
- 0
Results due
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2026-09-24 | mazdutide | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | P2 | 141 |
| 2026-12-31 | semaglutide | A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | P3 | 479 |
| 2027-05-07 | mazdutide | A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | P3 | 260 |
| 2027-10-31 | mazdutide | A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | P3 | 180 |
Trials on file
All 13 incretin trials recorded for this sponsor, active first.